Filtered By:
Specialty: Cardiology
Condition: Bleeding
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 3637 results found since Jan 2013.
Comparative Bleeding Risk in Patients with Atrial Fibrillation with Cancer versus Without Cancer from Nationwide Prospective Cohort
This study aimed to clarify the differences in the bleeding risk in patients with AF with cancers and those without cancers during the long-term OAC.The CODE-AF prospective registry enrolled 5,902 consecutive patients treated for AF at 10 tertiary referral centers in Korea. Of the enrolled patients, 464 (7.8%) were diagnosed with cancers and were followed for all stroke and bleeding events (net composite events).The age, CHA2DS2-VASC, and HAS-BLED scores were similar between AF patients with and without cancers. Male population greatly comprised patients with AF with cancers. They were equally prescribed with direct OAC co...
Source: International Heart Journal - September 13, 2023 Category: Cardiology Authors: Ki-Woon Kang David Shin Seung Young Shin Jun Kim Eu-Keun Choi Myung-Jin Cha Jung-Myung Lee Jin-Bae Kim Junbeom Park Jin-Kyu Park Tae-Hoon Kim Jae-Sun Uhm Jaemin Shim Young Soo Lee Hyung Wook Park Changsoo Kim Boyoung Joung Source Type: research
Associations of Apixaban Dose With Safety and Effectiveness Outcomes in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease
CONCLUSIONS: Compared with 2.5 mg, use of 5 mg apixaban was associated with a higher risk of bleeding in patients with atrial fibrillation and severe chronic kidney disease, with no difference in the risk of stroke/systemic embolism or death, supporting the apixaban dosing recommendations on the basis of kidney function by the European Medicines Agency, which differ from those issued by the US Food and Drug Administration.PMID:37681341 | DOI:10.1161/CIRCULATIONAHA.123.065614
Source: Circulation - September 8, 2023 Category: Cardiology Authors: Yunwen Xu Alex R Chang Lesley A Inker Mara McAdams-DeMarco Morgan E Grams Jung-Im Shin Source Type: research
Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis
CONCLUSIONS: Recruitment targets were reached, but many eligible participants declined randomization. There were numerically more bleeding events in patients taking rivaroxaban compared with control, but rates of bleeding and recurrent venous thromboembolism were low overall and in keeping with previous studies. Participants had symptoms affecting their well-being at enrollment but improved over time.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT03178864.PMID:37675613 | DOI:10.1161/STROKEAHA.123.044113
Source: Atherosclerosis - September 7, 2023 Category: Cardiology Authors: Thalia S Field Vanessa Dizonno Mohammed A Almekhlafi Fouzi Bala Ibrahim Alhabli Hubert Wong Monica Norena Maria Karina Villaluna Princess King-Azote Namali Ratnaweera Steven Mancini Stephen C Van Gaal Laura K Wilson Brett R Graham Luciano A Sposato Dylan Source Type: research
EP News Clinical
Kirchof and colleagues (N Engl J Med. 2003; epub Aug. 25: PMID: 37622677) conducted a, double-blind, double-dummy, randomized trial of patients> 65 years with device-detected atrial high-rate episodes (AHREs)> 6 minutes. Patients were randomized to edoxaban (E) or placebo (P). The primary efficacy outcome was a composite of cardiovascular death, stroke, or systemic embolism. The safety outcome was a composite of death from any cause or major bleeding. Overall, 2536 patients were randomized, including 1270 to E and 1266 to P.
Source: Heart Rhythm - September 7, 2023 Category: Cardiology Authors: N. A. Mark Estes Source Type: research
EP News: Clinical
Kirchof et al (N Engl J Med August 25, 2003; https://doi.org/10.1056/NEJMoa2303062, PMID 37622677) conducted a double-blind, double-dummy, randomized trial of patients 65 years and older with device-detected atrial high-rate episodes lasting for ≥6 minutes. Patients were randomized to edoxaban (E) or place bo (P). The primary efficacy outcome was a composite of cardiovascular death, stroke, or systemic embolism. The safety outcome was a composite of death from any cause or major bleeding. Overall, 2536 patients were randomized, including 1270 to E and 1266 to P.
Source: Heart Rhythm - September 7, 2023 Category: Cardiology Authors: N.A. Mark Estes Tags: EP NEWS Source Type: research
Direct Oral Anticoagulants: Patients Benefit When Prescribers Get the Message
Direct oral anticoagulants (DOACs) have demonstrated similar or better efficacy to warfarin in reducing stroke and systemic embolic events in large-scale prospective trials.1 –4 In addition, these trials demonstrated either noninferiority or superiority in reducing bleeding events compared with warfarin. To treat high-risk patients with atrial fibrillation (AF) and avoid bleeding in low-risk patients, current guidelines recommend oral anticoagulants in high-risk patien ts with AF with CHA2DS2VASc scores of ≥2 in men and ≥3 in women.
Source: The American Journal of Cardiology - September 5, 2023 Category: Cardiology Authors: Gerald V. Naccarelli Tags: Editorial Source Type: research
Intracranial haemorrhage in acute myocardial infarction: A rare but dramatic complication
The shift from thrombolysis to primary percutaneous coronary intervention (PCI) and the use of multidrug antithrombotic therapy in the management of acute myocardial infarction (AMI) have led to both a substantial improvement in outcomes and a reduction in bleeding complications [1,2]. In particular, in AMI, the rate of haemorrhagic stroke, the most dreaded haemorrhagic complication, decreased by 50% from 1998 to 2008 [1]. Despite its low incidence, intracranial haemorrhage (ICH) is often devastating, being associated with severe disability and high mortality rates.
Source: International Journal of Cardiology - August 29, 2023 Category: Cardiology Authors: Filippo Trombara, Nicola Cosentino, Giancarlo Marenzi Tags: Editorial Source Type: research
Outcomes of aortic valve-sparing root replacement with cusp repair in connective tissue disease
CONCLUSION: Remodelling and aortic valve repair showed excellent durability at 5 years, even in connective tissue disorders.PMID:37640626 | DOI:10.1016/j.acvd.2023.07.005
Source: Archives of Cardiovascular Diseases - August 28, 2023 Category: Cardiology Authors: Pichoy Danial Pierre Demondion Mathieu Debauchez Pascal Leprince Emmanuel Lansac Source Type: research
